Kailera Therapeutics (NASDAQ:KLRA) Research Coverage Started at Canaccord Genuity Group

Canaccord Genuity Group initiated coverage on shares of Kailera Therapeutics (NASDAQ:KLRA) in a research note issued to investors on Monday morning, MarketBeat reports. The firm issued a buy rating and a $44.00 target price on the stock.

Separately, Weiss Ratings upgraded Kailera Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research note on Wednesday, October 21st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Kailera Therapeutics has an average rating of “Moderate Buy” and an average target price of $43.00.

Kailera Therapeutics Price Performance

Kailera Therapeutics stock opened at $14.38 on Monday. Kailera Therapeutics has a 1-year low of $9.76 and a 1-year high of $28.23. The stock has a market cap of $1.87 billion and a PE ratio of -0.00. The stock’s fifty day moving average is $12.66 and its two-hundred day moving average is $17.60.

Kailera Therapeutics (NASDAQ:KLRA) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.55) by $0.81. On average, research analysts expect that Kailera Therapeutics will post -3.71 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kailera Therapeutics

Hedge funds have recently made changes to their positions in the company. Atlas Venture Life Science Advisors LLC purchased a new stake in shares of Kailera Therapeutics in the 2nd quarter valued at about $113,923,000. Wellington Management Group LLP acquired a new position in Kailera Therapeutics during the second quarter worth approximately $64,308,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Kailera Therapeutics during the second quarter worth about $24,233,000. State Street Corp acquired a new stake in shares of Kailera Therapeutics during the second quarter worth $19,126,000. Finally, Aberdeen Group plc increased its position in Kailera Therapeutics by 209.0% during the 3rd quarter. Aberdeen Group plc now owns 432,661 shares of the company’s stock worth $4,941,000 after purchasing an additional 292,661 shares during the period.

Kailera Therapeutics Company Profile

Kailera Therapeutics is a clinical-stage biopharmaceutical company developing medicines for obesity and related metabolic diseases. Its research focuses on treatments that act on biological pathways involved in appetite, weight regulation and metabolism. The company’s pipeline includes investigational injectable and oral therapies, including programs designed to target GLP-1 and GIP receptors. These products are in development and are not approved for commercial use. Founded in 2024, Kailera has secured development and commercialization rights outside Greater China to drug candidates discovered by Jiangsu Hengrui Pharmaceuticals.